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Abstract
Background. Insulin pumps are essential in the management of type 1 diabetic pediatric patients
because of their versatility in meeting the developmental needs of childhood and adolescence.
Summary of the Evidence. There is lack of evidence for standardized pump initiation program in
pediatric patients (ADA, 2019). Moreover, adverse events from insulin pump misuse, such as
diabetic ketoacidosis, arise from lack of anticipatory guidance of pump management and
troubleshooting (Evert et al., 2016; Grunberger et al., 2014, Wheeler et al, 2014). Project
Purpose. The purpose of this quality improvement (QI) project was to reduce and prevent
adverse outcomes of insulin pumps secondary to an inefficient initiation process, management,
and patient/family understanding. Project Objectives. Objectives of this QI were: the
implementation of a streamlined initiation process, assessment of patient knowledge through an
additional education session including a pre-and post-test patient skills questionnaire, and to
decrease adverse effects related to new insulin pump use. Results. 100% staff education was
achieved, 67.5% of patients/families attended the new education session achieving an average
score of 80% or higher on the skills questionnaire, and adverse effects related to new insulin
pump usage decreased from a rate of 66% to 50% after implementation. Implications for
Practice. Use of practice guidelines to implement a structured process for insulin pump initiation
is a cost-effective strategy to promote patient ownership, improve patient knowledge, lower
potential costs of clinic or hospital visits for adverse effects, and guide provider oversight in
effective use of technology to improve patient outcomes and decrease barriers to care.
Keywords: Insulin pumps, pediatric type 1 diabetes, CSII, insulin pump initiation

INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES

9

Readiness for Insulin Pump Use in Pediatric Type 1 Diabetes:
A Quality Improvement Project
Type 1 diabetes mellitus is a chronic disease most common in children and adolescents,
which is marked by an autoimmune process requiring the need for a lifetime of exogenous
insulin dependence. According to the Centers for Disease Control and Prevention (CDC, 2017),
during 2011-2012, there were 17,900 new diagnosed cases of type 1 diabetes in the United States
in individuals younger than 20 years old. This chronic disease commonly affects non-Hispanic
whites. However, Mayer-Davis et al. (2017) stated that between 2009-2012, Hispanic children
and adolescents had an annual 4.2% higher incidence rate of type 1 diabetes than non-Hispanic
whites. Currently, data about the incidence and prevalence of pediatric type 1 diabetic cases in
the state of Texas, nor Bexar County are available. However, these national statistics exhibit
implications for need of improved management of pediatric type 1 diabetes within its
populations.
The landmark Diabetes Control and Complications Trial highlighted the importance of
intensive insulin treatment to prevent the progression of both macrovascular and microvascular
comorbidities (Diabetes Control and Complications Trial Research Group, 1993). As a result of
this clinical trial, the American Diabetes Association’s (ADA, 2018) clinical guidelines
recommend tight metabolic control through strict insulin administration partnered with
adherence to daily blood glucose monitoring, a carbohydrate-controlled diet, and active lifestyle
to guide optimal health outcomes. It is imperative for pediatric type 1 diabetic patients to
maintain therapeutic management since childhood is a crucial period for brain development and
continuous maturation of brain functions (ADA, 2018). Therefore, this population has an
increased risk for neurocognitive complications from diabetic ketoacidosis (DKA), such as
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cerebral edema, hypoglycemia, seizures, and altered mental status (Cameron et al., 2014).
Moreover, diabetic children just like diabetic adults are at risk of macrovascular comorbidities
such as hypertension and atherosclerotic disease, as well as, microvascular complications, such
as peripheral neuropathy and retinopathy (ADA, 2018).
Although insulin pumps have existed for over 30 years, due to advancements in emerging
health technologies in the past two decades, continuous subcutaneous insulin pumps (CSII) have
become essential in type 1 diabetic care for pediatric patients because of their versatility in
meeting the unique needs of children and adolescents. A significant barrier to achieving
metabolic control within this population is disease burden due to changes in growth and
development that influence insulin sensitivity, changes in parent and child roles, and need for
external psychosocial support (ADA, 2018). Therefore, providers must meet the challenge of
creating individualized treatment regimens that meet standards of care to achieve glycemic
control, prevent complications of the disease, and are conducive to a healthy childhood
(Woerner, 2014).
Ehrmann et al. (2018) stated that in contrast to multiple daily injections (MDI), CSII
therapy can replicate the body’s physiologic function of insulin secretion through advanced
insulin infusion settings allowing for basal and bolus rates and advanced technology that provide
real-time data of the body’s insulin needs. CSII therapy is a tool that individualizes care for
children and adolescents due to their increased energy and metabolic needs and allows for
normality of care in the management of type 1 diabetes. Insulin pump therapy also lessens the
burden of multiple daily needle sticks, a significant stressor of diabetes management in pediatric
populations. CSII pump therapy requires a one-time injection every 2 to 3 days compared to
multiple daily injections for insulin administration (Sherr et al., 2018; Woerner, 2014). However,
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the success of adhering to insulin pump therapy in children and adolescents is dependent on the
patient and family readiness to transition from MDI to CSII. Preparation for insulin pump use is
determined through education, health literacy, access to care, and continuation of a therapeutic
relationship with the healthcare team.
Statement of the Problem
The selected DNP project site was an urban pediatric endocrinology clinic located in
south Texas. The problem was the lack of a standardized protocol for the providers’ initial
readiness assessment and for the continuous evaluation of barriers to successful insulin pump
adherence with children and adolescents. It is essential for providers to assess the pediatric
patient’s motivation to adhere to the use of this technology and anticipate needs, such as health
literacy, cost/medical insurance, and social support that can create obstacles in the transition
process from multiple daily insulin injections to use of a wearable continuous insulin infusion
pump (Grunberger et al., 2014). Furthermore, providers must be capable of managing these
devices to provide satisfactory patient education that will improve patient outcomes related to
their diabetes, such as decreasing the hemoglobin A1C level, preventing hypoglycemic events,
and decreasing symptoms of hyperglycemia. Also, clinical providers must reinforce the training
by being part of a diabetic care team which provides holistic clinical support during the transition
to CSII pump therapy (Grunberger et al., 2014; Shulman et al., 2016).
Background and Significance
The cornerstone of diabetic care and management is aimed at preventing the progression
of disease morbidity and comorbidity. Complications of mismanaged type 1 diabetes in children
can have debilitating pathophysiological complications that affect the neurologic, cardiovascular,
and urinary systems. The body’s central nervous system uses glucose to carry out essential
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cognitive and sensorimotor functions which can be easily disrupted by frequent abrupt
imbalances of normoglycemia. Hypoglycemia can impede cognition, causing altered mental
status, hypoglycemia unawareness, and fatal seizures (Bratina et al., 2018; Cameron et al., 2014).
On the other hand, hyperglycemia can also cause altered cognition, diminish body energy, and
result in a medical emergency such as DKA (Bratina et al., 2018; Cameron et al., 2014). These
glycemic extremes can also stress peripheral nerves causing progressive sensorimotor loss
exhibited by retinopathy and peripheral neuropathy (Donaghue et al., 2018). In the
cardiovascular system, macrovascular complications are related to the early development of
hypertension and hyperlipidemia increasing the risk for cardiovascular disease especially for
adolescents with type 1 diabetes (Donaghue et al., 2018). Moreover, the lack of glycemic control
also affects the urinary system through alterations of renal function and morphology that can
result in progressive loss of kidney function (Donaghue et al., 2018).
With advanced diabetic technology, routine diabetic care is not enough to prevent
complications of type 1 diabetes, and additional competence, knowledge, and responsibility are
required. Currently, consensus among clinical guidelines for the use of diabetic technology
recommend criteria for insulin pump use in pediatric patients to include the ability to selfmonitor blood glucose at least four or more times a day, lack hypoglycemic control despite
adherence to MDI therapy, fluctuating glucose levels from day to day, and recurrent episodes of
hypoglycemia (ADA, 2019; Grunberger et al., 2014; Sherr et al., 2018). However, without
adequate education, resources, and efficient communication between patients/ families and the
multidisciplinary healthcare team during the initiation of CSII therapy, informed clinical
decisions cannot be made even if guideline criteria are met. Providers must increase their
awareness of modifiable and nonmodifiable barriers to insulin pump initiation. Modifiable
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barriers are health literacy, problem-solving in the event of a pump malfunction/accidental
discontinuation, and overall family and social support of using an insulin pump.
Pulgaron et al. (2014) identified that the patient and family’s level of health literacy,
especially numeracy skills, is a significant predictor of successful pediatric diabetes management
and glycemic control. Pulgaron suggested the use of the Diabetes Numeracy Test, a valid
screening tool that tests numeracy skills used in standard diabetic education such as insulin-tocarbohydrate ratio and interpretation of blood glucose levels to insulin coverage, as part of
routine diabetes care. Evaluating the degree of competence in these necessary skills prior to
insulin pump initiation is crucial because the patient and his or her parents will be required to
learn new terminology that involves knowing how to adjust insulin pump settings for basal and
bolus rates which are also dependent on blood sugar monitoring and an insulin-to-carbohydrate
ratio (Hirose et al., 2012). The benefits of advanced pump settings are that they help decrease the
risk of hypoglycemic events since they tailor insulin administration to meet a child’s day-to-day
activities/ energy needs and insulin sensitivity trends (Sherr et al., 2018).
Patient and parental knowledge of advanced insulin pump settings and understanding of
pump alarms influence their ability to troubleshoot their pump in case of a pump malfunction.
Results of a prospective study by Wheeler et al., (2014) exhibited increased adverse effects, such
as diabetic ketoacidosis or blocked insulin delivery, in children younger than 10 years old.
Therefore, providers must educate parents about realistic, anticipatory challenges in
acknowledging pump malfunction due to their child’s age and development. Problems that
present in early childhood are the growth of autonomy, increased susceptibility to illness, the
variability of diet and physical activity, and lack of ability to verbalize or identify signs and
symptoms of both hypoglycemia and hyperglycemia (Markowitz et al., 2015). In contrast,
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though adolescents may have the understanding and developmental skills to manage the
technology of insulin pumps, too much autonomy in their diabetes care can also increase the risk
of adverse effects through a lack of adherence to diabetes care management (Markowitz et al.,
2015). In anticipation of these challenges, the American Academy of Clinical Endocrinologists/
American College of Endocrinology (AACE/ACE) guidelines recommend that healthcare
providers distribute a diabetes action plan prior to pump initiation to patient and families to help
guide them in how to assess their pump, reinstate a new pump, or if needed, return to insulin
injection therapy for a short time frame (Grunberger et al., 2014).
Lastly, due to the increased skills needed to adhere to insulin pumps, overall
sociodemographic support outside the clinical setting can also present nonmodifiable barriers to
proper insulin pump initiation. Since children spend most of their day-to-day lives in school or
extracurricular activities, the provider and diabetes healthcare team need to assure
communication between a school nurse or teacher and partner with community resources, like a
support group, in order to enhance the child and the family’s transition to a pump and promote
continuity of regimen (Corathers et al., 2015). Moreover, the most significant barrier to obtaining
an insulin pump is medical insurance coverage, especially for minority pediatric patients, African
Americans, and Hispanics, and those with public health insurance or no health insurance
(O’Connor et al., 2018). In Texas, Sheikh et al., (2018) assert that despite increased coverage of
insulin pumps from Medicaid and CHIP, disparities in the use of insulin pumps in minority
groups and those with lower English proficiency persist. Additionally, evidence in the literature
suggests in the United States, higher HbA1c and lack of glycemic control are seen in minority
children with type I diabetes as well as those who have public insurance (Sheikh et al., 2018;
Watson et al., 2017). Awareness of these disparities can also prompt a provider to acknowledge
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any personal biases in their recommendations for insulin pumps and to offer comprehensive
learning materials that are culturally sensitive, easy to read, or are available in different
languages so that equity of insulin pump benefits is provided (O’Connor et al., 2018; Sheikh et
al., 2018; Shulman et al., 2016).
Organizational Assessment
A key component to improving clinical practice is through an assessment of the day-today functions and interactions between the clinical setting, the healthcare team, and its patients.
The selected site for this quality improvement project was a pediatric endocrinology outpatient
practice in south Texas. The clinic was located inside a comprehensive diabetes center from a
recognized healthcare system that is also an academic learning facility. The clinic not only seeks
to offer quality care to children with endocrinologic conditions in the urban area, but also those
from surrounding south Texas communities extending to the Rio Grande Valley. The top three
diagnoses treated in the clinic are both type 1 and type 2 diabetes mellitus, thyroid conditions,
and disorders of growth & development. Each provider sees between 16 to 18 patients a day,
with six to eight of them being diabetic patients.
The multidisciplinary diabetic care team consisted of five physicians, one family nurse
practitioner (FNP), three certified diabetes educators (two who are certified dieticians, and one
who is a registered nurse), and a licensed clinical social worker. Clinic hours ran Monday
through Friday from 7:30 a.m. to 4:30 p.m. The providers had set clinic days and a rotating oncall schedule during the week and weekends for patients’ admissions at two different hospitals in
the city. A minimum of two providers saw patients within a given day. Since it was a learning
facility, medical students, residents, and fellows also saw patients under the supervision of the
designated provider. The NP worked part-time and was in the clinic three times a week. At least
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one diabetes educator (CDE) was present every day, and they also had an on-call schedule to see
hospitalized patients due to a new diagnosis of diabetes. The licensed social worker was also
present in the clinic Monday through Friday but shared some responsibility in care coordination
for an additional pediatric subspecialty clinic. The supportive staff that were also present during
clinic hours were two front desk staff, three medical assistants, three LVNs, a nurse educator,
and the clinic supervisor who was a RN.
Since this clinic was part of a non-profit health system, most of the patient population had
Medicaid (Superior Star)/CHIP or were uninsured. However, as this was a pediatric subspecialty
clinic that served more than just the one urban community, the clinic also had a significant
population of patients with private health insurance. This clinic had a comprehensive,
interprofessional approach to care, which allowed them to have adequate resources to help
pediatric diabetic patients and their families afford high-quality care even with insurance
barriers.
The sociodemographic characteristics of the clinic’s type 1 diabetic patients were
predominately 82.1 % white and 19.4% of the total population spoke Spanish (see Table 1).
Three of the providers, the NP, and one CDE, spoke fluent Spanish, and one MA was also a
certified Spanish interpreter. Patients’ ages range from a couple of months old to 17 years of age.
The healthcare team follows ADA 2019 standards of care through focusing on health indicators
such as glycemic control by checking HbA1c in clinic every 3 months, offering continuing
diabetic education with a CDE at each visit, routinely communicating with patients and families
through phone calls, and providing resources of support for diabetes management such as access
to affordable medications and diabetic devices.
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Table 1
Demographic Characteristics of Clinic’s Type 1 Diabetic Population
Demographic

No. (%) of Patients
(n = 134)

Gender
Male
Female

86 (64.2%)
48 (35.8%)

Race/Ethnicity
White
Black, non- Hispanic
Asian
Other

110 (82.1%)
14 (10.4%)
6 (4.5%)
4 (2.9%)

Language
English
Spanish

108 (80.6%)
26 (19.4%)

Note. Data derived from clinic’s 2019 records.
In 2019, there were estimated 134 type 1 diabetic pediatric patients seen at the clinic, and
between 20-40 patients had started managing their disease with an insulin pump. While provider
preference determined to whom he or she recommended insulin pump therapy, there was no
standard protocol that they followed to initiate the insulin pump process or evaluate the patient
and family’s readiness for change. In meeting with three of the MDs and the FNP, a consensus
among their decision to start a patient on an insulin pump was determined by the patient’s ability
to consistently check blood sugars more than twice a day, have been diagnosed for more than a
year, be compliant with an adjunct care regimen such as carb counting, and have
parental/guardian support.
When a provider offered insulin pump therapy to a patient, the benefits of insulin pumps
to daily insulin injections were discussed. Due to clinic visit time constraints, the provider then
alerted the CDE to provide patient information brochures to the patient and family and they also
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briefly discussed the different types of insulin pumps. The patient and family were given time to
ask questions. Then, the CDE and provider encouraged the patient and family to look over the
information provided, to do some online research of their own, and to consult their insurance to
inquire what type of coverage they could obtain with the desired insulin pump. One barrier
identified in this step was that the patient and family were not always told to call the clinic back
when they had made a decision on a pump or that additional information was needed to order an
insulin pump, such as blood sugar logs 3 months prior and demographical information. The
CDEs verbalized that significant delays in the waiting period from when a pump is decided to the
time of the patient and family receiving the pump occurred because parents didn’t understand the
process of ordering a pump, or the importance of following through with their health insurance
about cost and coverage. Additionally, the LVNs and MAs verbalized breakdowns in current
communication between providers and CDEs regarding when to initiate the order for an insulin
pump, and lack of available patient data such as blood sugar logs that they needed to follow up
on, which also delayed the delivery of an insulin pump. On average, the waiting period for the
approval and delivery of an insulin pump from insurance companies, both public and private,
ranged from 1 to 4 months.
Once an insulin pump was delivered to the patient’s home, the family was expected to
notify both the insulin pump company representative and their clinic provider. The insulin pump
representative provided an insulin pump start class that covers the mechanical aspects and
settings about how to use the pump, and it was also the first time when the pump was placed on
the child. For this class to occur, the provider needed to be notified to write for insulin delivery
orders with the pump. This pump start class also took place in the clinic in an education room;
however, it was not considered an in-clinic visit. Rather it was a courtesy, free-of charge

INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES

19

education session provided by the representative for the insulin pump company. After this
session, the pump representative walked the patient family to the front desk for them to schedule
a follow up appointment within 1 week with the CDE to obtain more insulin pump education.
The provider may or may not see them on that visit, but providers stated that usually the patient
was seen within 3 months. The providers verbalized their awareness of issues with patient’s lack
of knowledge on how to use the device during the first months after insulin pump initiation,
which resulted in the self-discontinuation of the device or incorrect use of the pump. The CDEs
also verbalized issues with parents not understanding the importance of following up for pump
initiation class after receiving their pump.
Organization’s Readiness for Change
To assess the clinic’s readiness for a change process to take place, key stakeholders of the
diabetic care team were interviewed to gain perspective on what are the needs for improving the
insulin pump initiation process. Using the Practice Improvement Capacity Rating Scale, a
physician leader, the nurse practitioner, a CDE, and an LVN were interviewed to assess the
practice’s readiness for quality improvement to take place (Aligning Forces for Quality, 2014).
By using a scoring system, this tool also evaluates how current resources in practice can facilitate
change. Results from the interviews exhibited an average score of 200, which identifies the
practice that has a limited capacity initiation of a QI process (Aligning Forces for Quality, 2014).
The barriers identified during the interviews, are related to the lack of a QI officer or QI
team in place at this clinic that incorporates both providers and clinical staff. Past QI projects
were carried out by the provider team with little to no input of the clinic staff or have been QI
projects carried out by the larger health system with little provider input. There was also lack of
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communication between clinic staff and provider staff about change processes and initiatives due
to the lack of regular all clinical staff meetings.
A facilitator identified in these interviews was that both the clinical staff and the
providers recognized a need for a change process regarding a streamlined initiation process for
insulin pumps. The staff also recognized the need to have better team cohesiveness in quality
improvement initiatives so that everyone who is involved in patient care or interaction has a
voice. Overall, the staff showed support for improved communication strategies and were
motivated to take part in quality improvement initiatives.
Additionally, ten patients and their parents who had recently been recommended to start
an insulin pump therapy or had recently initiated a pump were interviewed to explore their needs.
The feedback provided by the patients and families revealed unawareness of insurance
coverage/cost and confusion about what to do when the pump arrives. Therefore, the cumulative
stakeholder interviews supported the need for an improved process of insulin pump therapy.
Project Identification
The purpose of this DNP quality improvement project was to reduce and prevent adverse
outcomes of insulin pumps secondary to an inefficient initiation process, management, and
patient/family understanding by implementing a streamlined process, increasing assessment of
patient management strategies, and improving patient education.
Project Outcomes
There were four project outcomes for this project. The first outcome was to streamline
the insulin pump initiation process and educate staff about the new process. The second outcome
was to increase patient and family knowledge about insulin pumps before starting CSII therapy
by incorporating an additional CDE visit before the insulin pump initiation. The third outcome
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was to increase the number of patients that receive appropriate standard of care insulin pump
management education. Lastly, the fourth outcome was to reduce the number of adverse events
related to pump mismanagement leading to decreased control of diabetes.
Anticipated Outcome Measures
1. By February 12th of 2020, 100% of staff and providers will receive education about the
new insulin pump approval process.
2. By August 1st of 2020, 75% of patients that have requested insulin pump therapy will
attend both CDE educations visits and receive appropriate pump management education.
3. Patient-level of knowledge will show improvement from pre-pump start education to
post-pump start secondary education, evidenced by achieving a score of 80% or higher on
both the diabetes care assessment test and pump terminology test. Also, patients will have
90% of the education checklist completed by post-insulin pump start visit.
4. By July 2020, there will be a 30% decrease of insulin pump-related adverse events
such as calls about pump malfunction or issues, and unexpected hospitalizations from the
current rate of 66% related to an insulin pump issue.
Summary and Strength of the Evidence
Guideline Recommendations
Evidence-based guidelines from the ADA, AACE/ACE, and ISPAD provided highquality evidence of the safety and efficacy of insulin pumps for child and adolescent type 1
diabetic patients (ADA, 2018; Grunberger et al., 2014; Sherr et al., 2018). The ADA (2018)
recommends that providers who initiate CSII therapy on pediatric patients must perform an
initial comprehensive patient readiness assessment which includes:
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Assessment of individual patient and family knowledge and health literacy regarding
CSII and diabetes management.

•

Selection of pump type (loop pump, closed loop, or CGM sensor augmented) and
prescribing initial pump settings.

•

Insurance coverage of insulin pump and supplies.

•

Family education about potential pump complications and pump failure action plan to be
prepared in an emergency, an episode of DKA, or a pump malfunction

•

Introduction and education of pump settings and terminology.
The ISPAD guidelines assert that an assessment of these focus areas aids providers in

exploring potential barriers to successful CSII therapy (Sherr et al., 2018). Nevertheless, the
three guidelines do not mention the use of valid screening tools or decision aids that can be used
to assess these potential barriers. Rather, the guidelines recognized the need for further research
and implementation of successful tools, frameworks, or clinical processes of cost-effective
insulin pump-focused diabetes education (ADA, 2018; Grunberger et al., 2014; Sherr et al.,
2018).
Benefits of CSII
There is limited evidence from systematic reviews and RCTs showcasing the success of
CSII in pediatric type 1 diabetes management over multiple daily injections for significant
improvement in HbA1c control over long-term periods. However, there is successful evidence of
the benefits of CSII over MDI therapy in children and adolescents (Ly et al., 2013; Rosner &
Roman-Urrestarazu, 2019; Yeh et al., 2012). Yeh et al. (2012) is a systematic review and
metanalysis that found CSII therapy to reduce hypoglycemic rates in children due to the usage of
certain pumps which incorporate a continuous glucose monitor device to correctly administer
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insulin based on real-time blood sugars or are sensor augmented to stop infusing when the blood
sugars are low preventing the administration of too much insulin. Ly et al. (2013) supported this
finding in an RCT that compared a sensor augmented insulin suspension pump group to a regular
pump group. Results of the study found a lower incidence of moderate to severe hypoglycemic
events, from 175 to 35, in the sensor augmented pump group compared to the regular pump
group, 28 to 16 (Ly et al., 2013). Hypoglycemia unawareness is a common symptom of pediatric
type 1 diabetic patients under the age of 12. Therefore, advance insulin pumps settings and
features are beneficial in preventing adverse effects.
Versality of care that CSII therapy provides has also been studied in a recent systematic
review focused on the association between health-related quality of life and pediatric type 1
diabetes management (Rosner & Roman-Urrestarazu, 2019). Out of the fifteen studies reviewed,
the researchers found improved pediatric quality of life scores and increased patient satisfaction
with the use of CSII therapy than MDI therapy from baseline to post intervention follow up. Yeh
et al., (2012) also stated increased patient satisfaction with diabetes management due to lack of
multiple daily needle sticks and flexibility of adjusting insulin basal and bolus rates with
activities that such as exercise or meal and snack times.
Many of the limitations seen in these studies are related to small sample sizes of child
participants. Recommendations offered by these systematic reviews and the RCT is the need for
better studies, like RCTs, that account for larger sample sizes, increased diversity in selected
participants, and studies with extended implementation periods to fully understand benefits and
complications of CSII use in children and adolescents and their long-term effects of morbidity
and mortality (Ly et al., 2013; Rosner & Roman-Urrestarazu, 2019; Yeh et al., 2012).

INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES

24

Provider Role in Management
Provider role in management of CSII therapy is crucial since providers can influence how
well a pediatric patient and his or her family adapt to new diabetes technology and how well a
patient adheres to its proper use. Markowitz et al., (2015) highlighted the importance of the
provider’s acknowledgment and understanding of the dynamic roles in diabetes management
between children and parents since growth and development of an individual child can influence
behaviors in care. An evidence-based strategy that providers can use with school age and
adolescent patients who are initiated on a pump therapy is motivational interviewing, a
communication style which reinforces a child’s personal motivational behaviors and tailors them
to specific care goals such as lowering A1c, better eating habits, increasing self-sugar checks
(Markowitz et al., 2015). Including the pediatric patient in the decision-making process of
selecting a pump they will feel comfortable in wearing and allowing them to be an active
participant in age-appropriate, shared responsibilities of diabetes care is another way that
providers can support successful insulin pump adherence (Grunberger et al., 2014; Markowitz et
al., 2015).
Another vital part of the provider role is the frequency and continuity of patient follow up
after insulin pump initiation to reassess how insulin pump therapy is benefiting an individual
patient. By ADA and ISPAD standard of care, children with insulin pumps need to be seen in
clinic every 3 months for routine care (ADA, 2018; Sherr et al., 2018). Moreover, Johnson et al.
(2013) found that additional patient education hours at pump initiation by a diabetic care team
and provider follow-ups phone calls in between routine clinic visits during the first months of
using a pump resulted in a decreased rate of diabetic ketoacidosis in the insulin pump group that
received education compared to standard diabetic care with MDI.
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Culture, Health disparities and Access
Cross-sectional studies found in the literature provided high-quality evidence of research
about potential strategies to overcome barriers to successful adherence to CSII in pediatric type 1
patients. Shulman et al., (2016) highlighted the importance of provider self-awareness of any
personal biases for whom they recommend insulin pumps to ensure health equity, as decreased
rates of insulin pump use are seen in minority children and families with public health insurance,
and low socioeconomic backgrounds. For that reason, providers must also be aware of current
insurance coverage for this type durable medical equipment since access to insulin pumps is also
influenced by cost. Despite increased Medicaid and private insurance funding for insulin pumps
in recent years, the cost of insulin pumps and supplies can range from $3,000 to $8,000 a year
(Sherr et al., 2018). Since CSII is notably more expensive than MDI therapy, a structured
education process for insulin pump initiation could be a cost-effective strategy to not only secure
the therapy benefits but also lower potential costs of frequent clinic visits or hospital admissions
due to therapy non-adherence.
Moreover, Sheikh et al. (2018) also stated that there are evident disparities in the equity
of insulin pump use in Spanish-speaking patients due to limited English proficiency and possible
low socioeconomic backgrounds. Implications for practice from this study recommend that
providers and clinics have comprehensive education materials in both Spanish and English or
provide readily available translation services to improve access to diabetic care technology
(Sheikh et al., 2018).
For low English-proficient individuals, health literacy is another contributor to the lack of
proper insulin pump use and access. Pulgaron et al. (2014) studied the relationship between the
health literacy independent variables of parental numeracy skills, parental reading skills, and
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parental perceived diabetes self-efficacy on type 1 diabetes glycemic control in a cross-sectional
study. The results of the study found an inverse correlation between higher parental numeracy
skills and lower HbA1c scores (r = −.52, p <.01) as well as higher parental self-efficacy and
lower HbA1c scores (r = −.47, p <.01) (Pulgaron et al., 2014). This study added to the
importance of providing the right education tools that reinforce of health literacy skills for
parents of type 1 diabetic children and the need for recurrent evaluation of these skills with
diabetic technology since its success relies heavily on parents having these skills to properly use
the device for their child’s disease management. By improving the delivery of care and
combating these barriers, providers can positively influence minority patients and low English
proficiency individuals to increase compliance with disease management and decrease unplanned
adverse events such as medication errors or emergency room visits.
Complications from Misuse of Pumps
Both human and technological factors can impact how well a patient succeeds in safely
using insulin pumps. Rosner and Roman-Urrestaruzau (2019), found that there was a higher
incidence of DKA in CSII therapy than MDI therapy and could be a result of human factors such
as pump malfunction, lack of knowledge of correct pump settings, and relaxed attitude to selfmanagement. Relaxed management is a significant factor in the case of a pediatric patient. A
child or adolescent may discontinue their pump without their parent’s knowledge due to factors
such as device discomfort or self-consciousness of body image in front of peers (Grunberger et
al., 2014). Blood sugar levels can rise quickly, 1mg/dL for every minute of being off the insulin
pump for more than 1 hour (Deiss et al., 2016). Additionally, when school age children and
adolescents are given too much independence in their diabetic care, such as being the ones
responsible for inputting their blood sugar data or carbohydrate counts into their pump, they can
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incorrectly put in data in an effort to not get in trouble for eating a snack that increased their
blood sugar, which will then prompt the pump to administer incorrect doses of insulin. These
actions can lead to detrimental effects of incorrect pump usage. Moreover, Deiss et al. (2016)
noted the importance of patient and parents in recognizing causes pump failure events. For
example, an interruption of insulin flow should be suspected with any insulin pump-dependent
patient that experiences unexplained glycemic variability, unexplained hyperglycemia, or
frequent hypoglycemic/hyperglycemic episodes (Deiss et al. 2016). With the help of
downloadable pump data, providers can also help recognize and evaluate these events prompting
education reinforcement for safe use of the devices.
Process of Initiation
There is lack of evidence evaluating a standard pump initiation program for pediatric type
1 diabetic patients (ADA, 2018). However, a recent RCT by Ehrmann et al. (2018) showed
promise of the efficacy of a structured program called Insulin Pump Treatment (INPUT) for type
1 diabetic adolescent and adult insulin pump users. In this study the intervention arm attended
the INPUT program which provided 12, biweekly, 90-minute group education sessions provided
by a diabetes educator and the control group received no intervention. Participants of the study
were between the ages of sixteen and seventy-five years of the sample population of n =266, n =
125 participants were in the intervention group. Significant results of this RCT showed that
INPUT group had an improved HbA1c scores (20.28% [23.1 mmol/mol]; P , 0.0001), had a
lower incidence of severe hypoglycemic events requiring help from another person, increase
self- reported use of pump advance settings, as well as decreased diabetes distress and depression
symptoms compared to the control group (Ehrmann et al., 2018). The success of this RCT
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highlights the need for studies that reflect the efficacy of structured insulin pump initiation and
management education in pediatric patients.
Methods
Project Intervention
The focus of the project implementation was to deliver a more effective transition to
insulin pump therapy process for patients and families. The details of this action plan are
provided in Appendix A. Before the implementation of the new streamlined process for insulin
pump initiation, the clinic staff and providers completed an education session given by the DNP
student. This education session was given in person during the February monthly staff meeting
and on an individual basis for those who were not able to attend. The DNP student provided a
handout to the staff outlining the new streamlined process. This handout was also emailed to all
clinic staff, and a printed copy was stored within the clinic protocol folder to be available for
staff reference.
Identification of Readiness for Insulin Pump Use
The new process began with the initial routine clinic visit when the provider decided if a
patient meets the guideline criteria for the initiation of an insulin pump. The provider introduced
the patient to insulin pumps and discussed how they differentiated from insulin injections and
their benefits to improve diabetes lifestyle and management. The CDEs distributed patient
education brochures, already available in the clinic, about the different types of insulin pumps.
Prior to implementation, this was all that occurred in the initial visit. However, in the
organizational assessment, the clinic staff recognized the lack of consistent information given to
patient families about the steps required before an insulin pump is ordered and delivered to the
patient. For this reason, a patient education handout that outlined the steps for preparing for
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insulin pump therapy, “Pathway to Insulin Pump Therapy”, was distributed to the patient and
family. This patient education handout (Appendix B) was made by the DNP student and written
at a 6th grade reading level in both English and Spanish. It was given at the end of the clinic visit
with the patient’s discharge paperwork. Both the providers and CDEs were responsible for
documenting, respectively, what was discussed, and the educational materials given to the
patient during this initial visit. The provider SOAP note also stated that part of the care plan is
for the patient to attend a pre-insulin pump education visit with the CDE. To encourage
continuity of care, during discharge, the front desk staff was responsible for making an
appointment for the pre-insulin pump education with CDE, which took place 3 to 4 weeks after
the initial visit.
Orders for Implementation
The second implementation step was a follow-up phone call by the LVNs to the patient
within 1 to 2 weeks of the original clinic visit when an insulin pump was discussed to inquire if
the family had decided on which insulin pump they wanted to use. The LVNs oversaw the
submission of diabetic device order forms to insurance companies; therefore, they also were
responsible for documenting this communication in the patient’s electronic chart and
messaging/communicating to the patient’s provider and CDEs about the family’s decision. With
the old process prior to implementation, there was no consistent follow through with the patient’s
family leading to miscommunication between the LVNs, the CDEs, and providers about the
patient’s decision and the personal information needed. This resulted in increased wait times for
insulin pump ordering. A facilitator for this step was that the clinic’s staff and providers use a
secure messaging system and the institution’s email to communicate about patient matters and
these messaging applications were used on a daily basis in the clinic by all staff. The LVN then
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notified the CDE through secure messaging about the patient’s insulin pump choice. Once the
CDE was notified, they were responsible for contacting the insulin company representatives to
alert them that they had a new patient with their device which helped speed up both the insurance
approval process and waiting period for insulin pump delivery to the patient.
Patient Education for Pump Utilization
In the past, the patient was not seen back in the clinic until the insulin pump was
delivered. At that time, an insulin pump start class was provided by the respective insulin pump
company representative in the clinic, but the patient was not be seen by a provider, nor one of the
CDEs. This was an area with a need for improvement because of the lapse in time since the
patient had been seen in the clinic and lack of re-evaluation for overall readiness for insulin
pump management. Therefore, an additional CDE education visit took place during the waiting
period of insulin pump approval/delivery, at least 1 month before the insulin pump start class
with the company representative.
The CDE visit focused on an introduction to the insulin pump ordered, assessment of
patient/family diabetic management skills, and pump malfunction emergency action plan. The
patient education visit took place in the clinic’s education room or available patient exam room
and would last about 1 hour. The DNP student made a checklist of the diabetic education to be
completed at this education session and finished at the follow up CDE visit post insulin pump
start (Appendix C). The CDEs used demonstration insulin pumps to allow the patient and their
family a first hands-on experience with their respective pump. The CDE screened the patient and
family for insulin pump readiness with two short tests created by the DNP student. The first
assessment, the Diabetes Pump Care assessment, was an eight-item test assessing the patient’s
diabetic management skills and pump care knowledge (Appendix D). The second test, the Insulin
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Pump Terminology test, assessed the patient’s and family’s level of knowledge about specific
terminology related to insulin pump settings (Appendix E). The CDE also created a
patient/family-centered pump malfunction emergency action plan with the help of the patient and
family. This plan described what to do with a possible pump malfunction or unexpected pump
disconnection. Once the plan was completed, the patient/caregiver was given a copy for their
home and another for the school nurse. The CDE also contacted the respective school nurse to
notify them about new insulin pump therapy.
The CDE would discuss with the family the importance of notifying both the clinic and
the insulin pump company representative when their pump is delivered to their home so that the
insulin pump-start class can take place. Once the education session is over, the CDE was
responsible for documenting what was discussed in the EHR, collect the tests and checklist, and
store them in the assigned project folder. At that time, the CDE was also responsible for
communicating to the provider that the patient attended the education visit so that the provider
could write a prescription for insulin delivery orders with the pump. This allowed the patient to
initiate pump therapy when they came in for their pump start-up class with the company
representative. If a patient did not show for the pre-pump start education session, the front desk
staff was responsible to contact them via telephone to reschedule the session.
Pump Initiation
Once the insulin pump was delivered to the patient, the patient and family attended the
insulin pump-start class with the pump company representative in the clinic. Before leaving the
clinic, the patient made an appointment for a follow-up education session with the CDE within a
week of pump initiation. During this 1 week follow up, the CDE re-tested the patient and family
about the Diabetes Pump Care assessment and the Pump Terminology test. At this time, if the
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patient was not able to attend the first education session, completion of the educational checklist
took place. In addition, the CDE was responsible for asking the patients if they had enough
prescription medication refills with their fast-acting insulin used for the insulin pump as well as
their basal insulin, which were needed in case of a pump malfunction. The CDE answered
questions about issues with the management of their insulin pump for the first week and inquired
about what the patient and family experienced. At the end of this educational visit, the CDE
prompted the front desk staff to help schedule a routine follow-up appointment with their
Pediatric endocrinologist within 2 to 3 months. The CDE then messaged the providers about who
was seen to prompt the provider to follow up with the patient and family by phone 1 week after.
Setting/Population
The quality improvement project was conducted at an outpatient pediatric endocrinology
clinic. In 2019, there were around 20 to 40 pediatric patients between the ages of 1 to 18 years
that were initiated on insulin pumps and currently close to 300 with them already in use. The
DNP student and mentor estimated that about 10 patients would participate in the quality
improvement project.
Organizational Barriers
A barrier present in this clinic was the lack of availability for provider appointments due
to the large population of patients seen at this clinic that are not type 1 diabetic patients. Initially,
the new streamlined process required the patient to have their 1-week follow-up with their
provider or at least 1 month post insulin pump start. However, in the organizational assessment,
the average rate of the next available appointment was 42 days, which is higher than the
benchmark goal of 14 days. The providers also voiced concerns that patients’ third-party
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insurance would not cover the additional follow up visit. So, it was decided a follow up phone
call would be included instead of an office visit.
An additional barrier was that the clinic had a change to a different EHR system during
the implementation process. Initially, none of the clinic staff had been trained on the new system
and training occurred at different intervals for each staff member. The change in EHRs caused
obstacles during data collection and effective communication regarding the patients’ status in the
new initiation process due to different charting processes and a new secure messaging system.
Barriers related to patients and families included lack of follow up communication
notifying the clinic about their pump selection or when the pump arrives to their home. Also,
lack of insurance approval of pump which required the provider to appeal the insulin pump order
and show more detailed soap notes and clinical data such as blood sugar logs to validate the
medical necessity of the device. These barriers also prolonged the wait time between pump
decision to pump initiation. Lastly, differences patient/family primary language can cause issues
since the insulin pump features are typically in English, not Spanish. Cultural barriers such as the
roles of caregivers can also affect who receives proper training with the patient. For example, for
toddlers and school age children, it is important for both parents or additional caretakers such as
a grandparent or nanny, to receive education since children in this age group tend to be taken
care of by additional adults outside of school hours, especially if the child is from a single parent
home or if both parents work full time.
Organizational Facilitators
A driving facilitator of this quality improvement project is that the providers, the CDEs,
and the clinic staff shared a common responsibility for improving patient outcomes with insulin
pumps, ensuring patient safety with the use of insulin pumps, and improving communication
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with each other. Another facilitator is that since the clinic sees a large population of Spanish
speaking patients and low socioeconomic backgrounds, the staff also recognized the need for this
change process to provide high-quality care for this population who they felt needed more help
in understanding and managing an insulin pump device. Also, the clinic has a reported 87%
patient satisfaction experience score for the past 2 months, which is close to, but still less than
their goal of 90%. Additionally, the clinic’s no-show rate is at 14%, which is less than the health
system cut off a benchmark of 20%. This gives a hopeful perspective that the patients and
families will be willing to attend the additional education visit and not miss it.
Ethical Considerations
The QI project exhibited limited physical risks and harm to the participants of the
interventions. No compensation was given to patients or families for participating. The QI
project offered a 6th grade reading level and language education materials to patients in both
English and Spanish. Additionally, translation services support was provided with the use of staff
certified translator or a tablet with video translation services app to ensure that correct
information was given to the participating families. Participants’ privacy and confidentially was
maintained and protected throughout the project. Paper checklists and forms with patient data
collection were maintained in the endocrinology clinic in an identified, confidential folder,
secured in the Mentor’s office at the clinical site. The paper checklists, patient tests, and
education checklist had a patient label placed on the paper, which was only used for these forms.
Electronic data remained under the DNP student’s Microsoft desktop at the clinical site with
assigned clinical site student login from the clinic’s health system.
The University of the Incarnate Word and the clinic site institutional review boards
reviewed the QI project to ensure its compliance with local, state, and university regulations
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before implementation. It was deemed as non-research by both institutions. The DNP student
also obtained approval and support from the clinical manager, interim pediatric endocrinology
department director, and mentor to implement the project and a letter of support was provided
(Appendix F).
Evaluation Plan
In order to evaluate the effectiveness of the new streamlined process and improvement in
patient outcomes, specific variables and data were measured and collected for each of the four
project objectives. First, before the implementation of the new insulin pump initiation process,
the clinic’s staff and providers were educated on new steps and project objectives. A sign-in
sheet captured the number of staff members who attended the educational training meeting or
who obtained individual learning from the DNP student. The goal was for 100% of staff to
receive education by February 1st of 2020, and data of attendance were completed by that time as
well.
Second, patient attendance to both CDE education appointments were observed. The goal
was for 75% of participating patients to attend both CDE education appointments. The variables
measured for this objective were the number of scheduled CDE pump education visits per week,
the type of CDE visit (pre-pump or follow-up post-pump), and the no show rate for both prepump visit and follow-up post-pump CDE visit. This data were collected on a weekly basis by
the DNP student. The DNP student collected the type of CDE visit through chart review of CDE
notes. The reports on no show rates and the number of scheduled visits were collected by the
front desk secretary.
Third, the level of patient and family knowledge improvement was measured with the test
scores from the Diabetes Care Assessment and Pump Terminology Test and the completed

INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES

36

education checklist of the CDE education appointment. The goal was for the patient and family
to make an 80% passing score on both tests and to have at least 90% of the education checklist
done by the second education session. The CDE collected these scores and checklist after each
visit. The DNP student reviewed the education checklist for completeness weekly, and the test
scores were reviewed weekly.
Fourth, the goal of decreasing 30% of adverse effects related to insulin pump misuse or
issues was measured by the number of unexpected phone calls/clinic visits and the number of
monthly patient hospitalizations or ER visits with insulin pump issues of patients initiated on
insulin pumps at the start of the project. These reports were collected by front desk staff on a
weekly and monthly basis. Furthermore, additional patient variables regarding adverse effects
collected were the level of HbA1c at the initial visit and routine provider visits, blood glucose
levels, the patient’s weight, growth curves, and signs and symptoms of uncontrolled diabetes
such as polydipsia, polyphagia, polyuria, and hypoglycemic events. These were collected
through chart review by the DNP student.
Results
Demographic Data
A total of eight type 1 pediatric diabetic patients were initiated on insulin pump therapy
during the implementation period, but a total of n =5 patients were able to complete the new
standardized process between February 2020 through June 2020. The mean age for the new
insulin pump patients was 10.2 years old with a mean baseline hemoglobin A1C of 9.4%. Of the
five patients who participated in the intervention, three were male and two were female, three
were White, two were Black non-Hispanic. Main caregivers that participated in the new process
with patients were two parents, two grandparents, and a guardian. Additionally, 80% of the
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patients who participated in the new process had Medicaid insurance and 60% of the
participating families were English speaking. See table 2 for demographic data of participants.
Table 2

Demographic Characteristics of New Insulin Pump Use Participants
Demographic

No. (%) of Patients
(n =5)

Gender
Male
Female

3(60%)
2(40%)

Race/Ethnicity
White
Black, non- Hispanic
Asian
Other

3(60%)
2(40%)
0 (0%)
0(0%)

Caregiver
Parent
Grandparent
Guardian

2 (40%)
2 (40%)
1 (20%)

Insurance
Medicaid/CHIP
Private
Self-Pay

4(80%)
1(20%)
0(0%)

Language
English
Spanish

3(60%)
2(40%)

Outcome 1
The first anticipated outcome was met by 100%. Successful training was achieved by all
clinic providers and staff about the new process through an education session before project
implementation. Though not every provider attended, education was provided on a one to one
basis by the DNP student to those who were not present during the education session so that
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prior to implementation of the new process all providers were trained appropriately and
understood their role in the project.
Outcome 2
Initially, 100% of the new insulin pump patients were scheduled for the new pre pump-start
education visit. However, only 62.5% of patients attended this visit and 37.5% did not attend, nor
reschedule their visit. On the other hand, the post pump-start visit had 100% attendance. The
combined attendance rate for both education visits was 62.5% attendance and 37.5% did not
attend. The anticipated outcome was not met at 75%; however, five out of the eight patients
received appropriate standard of care insulin pump management education.
Outcome 3
Five out of the eight patients/families were able to take the diabetes care assessment and
completed 100% of the CDE education checklist. All eight patients, however, completed 100%
of the CDE worksheet. Pre pump-education diabetes care assessment scores had a mean average
score of 38.7% and post-test scores showed a mean average of 85%. The outcome was partially
met. Additionally, 80% of the five patients who took the pre-pump class were able to achieve a
score of 80% and above (see Figure 1).
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Figure 1
Diabetes Pump Care Assessment Scores
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Outcome 4
At baseline from the last quarter of 2019, out of the nine patients that had begun using
insulin pumps, there were six different adverse events and one hospitalization related to pump
malfunction. The baseline rate of adverse events related to insulin pump use was 66%. After
implementation, only four adverse events from a total of eight new insulin pump users occurred,
50% adverse event rate: three hyperglycemia episodes and one pump malfunction. The
anticipated outcome to decrease the adverse event rate by 30% was not met. However, a 16%
decrease from 66% was seen (see Figure 2). Moreover, with the implementation of the new
process no hospitalizations related to insulin pumps were seen.
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Figure 2
Adverse Events Related to New Insulin Pump Use
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Discussion
While not all objectives were met, an essential outcome of this quality improvement
project was the implementation of a new standardized workflow process of insulin pump
initiation and pre-pump patient education at the facility. This allowed the use of a common
language regarding insulin pump initiation, and timely completion of DME orders for insulin
pumps by clinic staff, which decreased the waiting period for insulin pump delivery. Also,
providers completed insulin pump setting orders before pump-start. This change process
represents the use of an evidence-based approach of improving patient education and provider
oversight of patients initiated on insulin pumps supported by the American Diabetes Association
clinical guidelines for diabetic technologies (2019) and the American Association of Diabetes
Educators practice statement (2018).
Due to the COVID-19 global pandemic that occurred during the implementation period,
amendments to the project interventions were made for use through telemedicine. While
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additional challenges arose with the use of telemedicine for the pre-pump start education session,
it provided unique patient benefits such as decreased transportation costs, decreased missed time
from school or work, and additional clinical support and healthcare access. These benefits are
consistent with the literature that state a major benefit of telemedicine in chronic disease
management is the ability to provide cost-effective healthcare access and disease prevention by
allowing patients who live in rural areas or in low socioeconomic communities to have access to
their healthcare specialist from their home (Dougherty et al., 2014; Smith & Satyshur, 2016).
The situation also showcased the future sustainability of this quality improvement project due to
the versatility of the project interventions to be used with telemedicine since CMS allows for
reimbursement of diabetic education by providers and certified diabetes educators (Centers for
Medicare and Medicaid Services, 2020).
Moreover, a fifth outcome for the project was created due to the COVID-19 pandemic. In
order to adhere to best practice health measures during this time, it was crucial to track how
many insulin pump users had documented routine care measures of hemoglobin A1C, lipid and
thyroid panels, an annual influenza vaccine, and a blood sugar log. By ADA guidelines,
hemoglobin A1C, must be checked every 3 months to monitor disease management (ADA,
2019). Through a chart review of 54 insulin pump users, we found 62.5% had a documented
hbA1C, 50% had documented lipid and thyroid labs, 42.2% had a documented annual influenza
vaccine, and 36.3% had documented blood sugar logs. Capturing this data allowed the clinic to
identify insulin pump users who would otherwise be missed for preventive measures during a
pandemic where a majority of the patients are not being seen in clinic, nor going to get routine
labs.
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Relation to Other Evidence
Similar to larger studies regarding insulin pump use in type I diabetes pediatric patients
this QI project had a small sample size. Despite evidence of inequity of insulin pump use by
minority patients in the literature, this project showed that 90% of the new insulin pump users
had Medicaid as their insurance plan, 40% were African American, and 40% of the
patients/families spoke Spanish as their primary language. Moreover, while the intervention only
provided an additional 1-hour education session, the five patients/families that participated in the
extra class had less adverse events than those who did not participate. Two of the hyperglycemia
events were experienced by two patients that did not attend the pre-pump start class. Evidence
from the INPUT RCT supports that increased education prior to pump start can lead to improved
patient outcomes (Ehrmann et al., 2018). Another finding was that there were no hypoglycemic
events following pump initiation with the new process. A decrease in hypoglycemic events has
been noted with CSII therapy compared to multiple daily injections (Ly et al., 2013; Yeh et al.,
2012).
Limitations
A significant limitation during the implementation period of this quality improvement
project was the COVID-19 pandemic, which forced the project interventions to be carried out by
a different approach. In order to enforce public health department and government mandates of
social distancing to decrease virus transmission, 90% of clinic appointments were done through
telehealth, which prompted all CDE education visits as a non-priority appointment. Initially, our
first education sessions were canceled, and the providers of the clinic decided to defer the insulin
pump starts during the first month of the stay-home mandate. In addition, the clinical staff,
especially the CDEs, had limited training with telemedicine resources and limited knowledge of
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telemedicine billing for diabetic education visits. The clinic also had to accommodate to address
issues with HIPAA regulated telehealth apps. However, as patients received their pumps at home
and pump orders were prescribed, an opportunity arose for the project to continue with the help
of the provider team. As a result, the pre-pump education was carried out by two providers (the
DNP student’s mentor and the NP), and the DNP student through phone and video conference
with the patients/families. The DNP student also amended the interventions to be more
online/phone call friendly. Both assessments were combined into a PowerPoint presentation that
was emailed to the patient’s parent the day before the education and only the diabetes care
assessment was used in a pre and post-test before and after the education session (Appendix D).
Additionally, another limitation was the lack of patient/family access to a computer or
personal email to receive educational materials. For one of the six families, the education was
given orally over the phone since the parents did not have access to a computer or email. Though
it did not affect their scores on the post-education assessment, they were restricted on the
telehealth experience of video interaction and lack of availability of materials at hand to look
over, which can impact the patient and family’s understanding of insulin pump management.
O’Connor et al. (2018) stated that minority, low-income households who primarily have public
health insurance are noted to have less exposure to technology resulting in decreased comfort in
using it properly. This is a crucial barrier to long term provider oversight, and patient ownership
of insulin pump therapy since an advanced setting of insulin pumps is that patient data of insulin
pump administration can be uploaded to cloud software and made available to both the patient
and clinician. These comprehensive logs include information about insulin administration,
carbohydrate intake, and blood sugars levels providing an overview of a patient’s day-to-day
glycemic control with the use of a pump. Therefore, this patient data are as important as a

INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES

44

patient’s hemoglobin A1C level in diabetes care management since providers use a patient’s
comprehensive insulin pump log to assess where to make changes in insulin requirements in
relation to the patient’s glycemic variability.
A third limitation was the limited implementation time frame due to the COVID-19
pandemic for accurate capturing of improvements in long-term patient outcomes such as
improvements of HbA1c while being on pump therapy since changes can only be seen after 3 to
4 months. Additionally, since the insulin pump users only make up about 20% of the patient
population of the clinical facility, another limitation was a small number of participants for this
quality improvement project.
Recommendations
A multidisciplinary team approach that includes IT and data analysts is needed to sustain
this change process by further exploring the addition of the education checklists and
documentation of patient assessment scores in the facility’s EHR to keep track of patient issues
with insulin pump readiness or pump malfunction especially since the health system made a
switch to a comprehensive EHR. Gathering and quantifying data of clinic patients who were
admitted in the hospital for DM type 1 complications or had pump malfunction issues was
difficult to obtain during this project. However, access to a seamless EHR system that allows real
time provider notification of clinic patients who are admitted to the health system’s hospital or
seen in the hospital’s emergency room for a pump malfunction and DM type 1 complications
could improve tracking of patient outcomes and gaps in this clinical process.
Due to the impact of the COVID-19 pandemic, back up telemedicine resources, and
clinical staff education about state and insurance plan policies regarding telemedicine are vital.
Literature has shown that telemedicine as an adjunct tool to standard outpatient diabetes
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management can lead to optimal patient outcomes (Dougherty et al., 2014). It is a cost-effective
option to continued clinician oversight when patients are presented with barriers to care such as
lack of transportation, lack of in-clinic visit availability/ time constraints, and in this case, a
global pandemic. For this reason, additional ways to distribute the educational materials to
patients, especially for those without access to a computer, must be addressed. An innovative
way to address this issue would be by creating a pump therapy educational video or sound
recording that is uploaded to clinic’s website or assigned to the patient’s clinic portal account so
that it can be easily accessed through a cell phone, tablet or computer. This is a feasible idea
since a majority of parents and children currently have access to mobile devices or tablets that
have access to the internet.
Additionally, observations made by the two providers who participated in the project
implementation were the success of improved patient/family engagement and communication.
Both the providers agreed that educating the patients themselves and having that one-on-one
time through a video and/or phone call outside of the clinic setting allowed patients and parents
to be more comfortable in asking questions and voicing concerns they had in their diabetes
management. This is an area to explore for its effects on patient satisfaction. Perhaps, after
initiation of insulin pump therapy patients and families can request a telemedicine visit, whether
it be with a CDE or provider, to reinforce evaluation of proper insulin pump use or obstacles in
care instead of having to wait for an available in clinic appointment. This is an innovative
possibility of extending the patient-provider-healthcare team relationship.
Implications for Practice
Informed problem-solving skills in response to insulin pump failure was the focus of the
education provided in both education sessions. Evidence shows that adverse events from insulin
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pump misuse, such as DKA, arise from lack of anticipatory guidance of pump-troubleshooting
strategies (Evert et al., 2016; Grunberger et al., 2014; Wheeler et al., 2014). Evert et al. (2014),
recommended the use of a short waiting room questionnaire to be given to address insulin
infusion set issues during the clinic visit. Therefore, it calls attention to continue to carry out
quality improvement of continuous assessment of these patient skills at every future routine visit
to cue providers of education gaps.
Advanced practice registered nurses are experts of patient and family-centered care.
Therefore, they play a vital role in leading quality improvement by not only using evidencebased strategies that encourage patient ownership of insulin pump therapy, but also support
interprofessional collaboration and effective use of innovative technology and communication
methods to improve patient outcomes. The new protocol is a sustainable systematic change since
each staff member had their own responsibilities and the DNP prepared nurse was able to
initiate, guide, and support the implementation of evidenced-based standards of care. Through a
multidisciplinary approach and provider leadership, the project was able to be amended to use
telehealth. An additional sustainable outcome was that after discussion of the project results with
the provider team, the chief department head requested that the patient educational materials be
incorporated into the medical residents’ educational curriculum in order improve future pediatric
provider competence of insulin pump management. Ultimately, it is the provider’s responsibility
to assess patient/family readiness for change in therapy as well as to monitor patient outcomes. A
DNP prepared nurse recognizes this responsibility by tailoring the change process to decrease
health disparities and barriers to care.
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Appendix A
Action Plan for Project Implementation

Action Plan
Task

Arrange an education
session/meeting to
introduce QI measure
to staff

Materials

Space

Finance /
Budget

Personnel

N/A—inform
staff of the
upcoming
meeting
through email
and in person.

Office

Create teaching
handout for education
session of staff.

Computer and
printing paper

n/a

No Cost will print
handout
(15 pages)
in office

Print by January DNP student
28th.

Create teaching
materials for project
intervention

Student’s
computer and
printing paper

n/a

No
associated
cost

Estimated 1-2
hours to create
each handout.

•
•

Teaching
checklist
Patient
education
handout
“Pathway to
Insulin pump
Therapy”

No
associated
cost

Time Frame

Verbally inform DNP Student
staff of
meeting; 1 min

Send email by
January 24th.

Create all
materials by
January 17th.

DNP student
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•

Diabetes
Numeracy Test
• Insulin Pump
terminology
Test
• CDE education
checklist
Obtain approval of
materials from project
advisor.

Insulin Pump
educations
materials.

Office

No cost
associated

Communication
with project
advisor; 20
mins

DNP student and
project advisor

Education
Session/Introduction of
QI measure to staff

Teaching
Handout about
QI.

Educati
on room
in TDI.

Meal
(estimated
cost-$25)

30-min
education
session to take
place before
initiating QI
project.

All staff
members—MDs,
NP, CDEs, MAs,
clinic manager,
and front desk
receptionists

No cost
associated
with
printing

To be scheduled
for Friday
February 7th,
0800-0830.

Obtain buy-in and
input of staff regarding
QI measure

N/A—
Office
communication
with staff

No
associated
cost

Communication DNP student and
with staff
staff
regarding QI
project; 20 mins

Place copy of
streamlined QI project
at MA/Nurse station in
protocols folder

Checklist

Cost of
printing
the
handout

Before
initiating QI
project; 1 min

And in provider
workroom

Lobby/
Front
Desk
Provider
work
room

DNP student
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Place confidential
folder for completed
education packet that
includes tests and CDE
checklist in provider
office

Designated
folder for
confidentiality
of education
tests and
checklist
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Provider Cost of
Before
office
folder
initiating QI
(estimated project; 1 min
cost $2.00)

DNP student

Initial Provider Visit
Check-in patient

Sign-in sheet,
patient chart,
copy of
insurance

Lobby/

N/A—
already a
process
practiced
and funded
by the
clinic

At the start of
every
appointment;

Call back to patient
room and obtain
patient’s vital signs

Chart with labs
and SOAP
note, medical
equipment—
BP cuff,
hemoglobin
A1C, upload of
glucometer log

Hallway
and
patient
exam
room

N/A—
process of
the clinic;
MA paid
by health
system

After receiving
patient chart;
the start of the
patient care
process; 5 mins

Medical Assistant

Documentation of
patient’s medication
and blood sugar log
from glucometer if
with patient

EMR

Patient
exam
room

N/A—
process of
the clinic

At the
beginning of
patient’s
appointment; 5
mins.

Medical
Assistant

Physician enters room;
assesses patient and
evaluates eligibility for
insulin pump therapy

Stethoscope,
log of blood
sugars, most
recent A1C
result, SOAP
note

Patient
exam
room

N/A—
process of
the clinic

During patient’s
appointment; 20
mins

Physician

Front
Desk

Front Desk
Receptionist

5 mins
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Physician documents
treatment plan—child
meets eligibility for
insulin pump therapy

SOAP note,

CDE enters room;
provides patient and
family brochures about
different insulin pumps
and “Pathway to
Insulin Pump Therapy”
handout

CDE note in
EMR
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Patient
exam
room

N/Aprocess of
the clinic

During patient’s
appointment

Patient
exam
room

No costbrochures
are
available
in clinic;
patient
education
handout
printed in
clinic

During patient’s
appointment

Physician

5 mins
CDE

5-10 min

Already a
clinic
process
Patient check-out

n/a

Hallway
or Front
Desk

N/A

Conclusion of
patient’s
appointment; 5
mins

Contacting
patient/family about
insulin pump decision

Office
phone &
patient
EMR

LVN
station

N/A

Patient will be
called 2 weeks
before
scheduled CDE
education

Medical Assistant,
Front Desk
Receptionist

LVN

2-5 min
CDE Pre-pump
education session

Education
packetChecklist of
education
topics,
Diabetes Care
assessment
test,

Educ.
room

No Cost of
printing
education
materialswill be
printing
them in
office)

Education
session will
take 1-2 times a
week during
implementation
period.
Allotted 1-hour
period

CDE
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Terminology
test,

Will be
Scheduled to
take place
Mondays or
Fridays

Completed
education tests
& checklist
will be placed
in secure
confidential
project folder
in provider
office
CDE messages
Provider of session and
Provider writes Insulin
Pump orders

EMR

Pump-Start Education
Session

n/a

Office

n/a

1-3 min

CDE & provider

Educ.
room

n/aprovided
by insulin
pump
company;
already a
clinic
process

Usually takes
place 1-2 times
a week.

Pump
Representative

No Cost of
printing
education
materialswill be
printing
them in
office)

Should take
place one-week
post pump start.

Insulin pump
order form

Schedule post pump
CDE education visit at
end of this visit.

Post Pump- start CDE
education session

CDE charts in SOAP
note about completed

Complete
Educ.
education
room
checklist, retest
diabetes
assessment test
and pump
terminology
test, Insulin
pump Action
plan

EMR SOAP
note

Office

n/a

1-2 hrs

CDE

Allotted time -1
hour
Mondays or
Fridays

5 min

CDE
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education session and
messages provider of
completed education

Provider receives
message and calls
patient and family by
phone

Office Phone

Office

n/a

3-5min

Provider

Should take
place within a
week after last
education
session with
CDE
DATA COLLETION

100 % of staff will
attend education
session

Sign in- sheet

Office

75% of participating
patients to attend both
CDE education
appointments

Excel sheet

Office

o The number of
scheduled CDE
pump education
visits per week
o The type of CDE
visit ( pre-pump or
follow-up postpump),
o The no show rate
for both pre-pump
visit and follow-up

Patient EMR

N/A

N/A

Will be
collected
during first
education
session and on
one-one basis
within first
week of project
implementation

DNP student

30 mins-1 hour

DNP student and
Front desk
secretary

Collected
weekly
Fridays or
Mondays
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post-pump CDE
visit.
The patient and family
to make an 80%
passing score on both
tests and to have at
least 80% of the
education checklist by
second education
session

Decreasing 30% of
adverse effects related
to insulin pump misuse
or issues is measured
by the number of
unexpected phone
calls/clinic visits and
the number of monthly
patient hospitalizations
or ER visits with
insulin pump issues

Education tests
Education
Checklist

Excel sheet
EMR

Folder
and
filing
drawer
in
mentor
office

N/A

Office
comp.

N/A
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The CDE will
CDE and DNP
be collecting
student.
these scores and
checklist at
every visit (12x a week).
The DNP
student will be
reviewing the
education
checklist test
scores for
completeness
weekly.
Unexpected
phone calls or
visits to the
clinic will be
collected
weekly by front
desk and
providers.
Hospitalizations
or ER visits will
be collected
monthly.

•
•
•

Provider
Front desk
DNP Student
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Additional staff
Results of the
meetings and education QI measure
sessions

Office’s
break
room

Meal;
costs of
any paper
to print out
visual
diagrams
of the
results of
QI
measure

60
30 min.
meetings/educ.
session during
the staff’s lunch
hour
o A meeting
will be
scheduled at
the half-way
point of the
QI project
o Additional
meetings
may be
scheduled if
there are
any issues,
questions,
or concerns

DNP student; all
staff members
including MD,
MA, OM, and
front desk
receptionist

Appendix B
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Appendix C

CDE Education Checklist for Pump Therapy
TOPIC
Understating Pump Therapy
 Insulin Type
 Basal Rate
 Meal Bolus
 Insulin Sensitivity/ Correction Factor
 Infusion Set
 When to change Set
 Pump Terminology Quiz: _______ score
Skin Safety
 Checking pump placement
 Lipohypertrophy
 Rotating sites
Blood Glucose Testing
 Schedule while on pump
 A1c
Nutrition
 Carb counting
 Using Food Labels
 Insulin to carb ratio
 Correction scale
 Proper Snacks
 Diabetes Care Assessment: ______ score
Exercise
 Pump Safety
 BG checks
 Hypoglycemia
 Proper snacks
Hypoglycemia/ Hyperglycemia/ DKA
 Diabetes Action Plan
 Signs and Symptoms
 Ketone testing
 Glucagon
 Sick Days
Pump Therapy
 When to call the doctor/clinic
 What do if pump fails or is discontinued
 How to order pump supplies
 Pump back up Plan
 Pump Orders: date__________________

DATE

INITIALS
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Appendix D
Diabetes Pump Care Assessment in English and Spanish

Diabetes Pump Care Assessment
Circle the correct answers.
1. Which type of insulin is used in insulin pump therapy?
A. Fast acting
B. Long Acting
2. Which is a fast-acting insulin? Circle the correct answers.
A. Lantus
B. Humalog
C. Tresiba
D. Novolog
3. When using a pump, which type of insulin delivery should keep blood sugar stable
when you are not eating?
A. Basal
B. Bolus
C. Temporary Basal
4. When using a pump, which type of insulin delivery is used to cover food eaten or to
lower a high blood sugar?
A. Temporary Basal
B. Basal
C. Bolus
5. If your child has an unexpected high blood sugar and you give them a correction
dose of insulin with their pump, when should you recheck their blood sugar to make
sure the pump is working properly?
A. Every 15 minutes for 1 hour
B. 30 minutes after
C. 1 hour after
6. If your child’s blood sugar does not go down after a correction dose given with the
pump, what is the first thing should you do?
A. Call your provider
B. Trouble shoot your pump
C. Call 911 or go to ER
7. What is the longest amount of time your child can be disconnected from their pump
before you need to check their blood sugar?

INSULIN PUMPS & PEDIACTRIC TYPE 1 DIABETES
A.
B.
C.
D.

30 min
1 hour
3 hours
4-5 hours

8. If your pump fails, you are told to follow the sliding scale shown here.
Insulin you take
Units of
based upon your Insulin
blood sugar
levels.
If Blood sugar
is:
0-150
0
151-200
1
201-250
2
251-300
3
301-350
4
351-400
5
8a. How many units would you take for a blood sugar of 295? _____units
8b. What type of insulin would you use if your pump stops working?
A.
B.
C.
D.

Humalog and Lantus
Tresiba only
Novolog only
Tresiba and Lantus
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Revisión del Cuidado de Diabetes
con el Uso de Una Bomba de Insulina
Encierre en un círculo la respuesta correcta
1. ¿Qué tipo de insulina se usa en la terapia con bomba de insulina?
a. De acción rápida
b. De acción larga
2. ¿Qué es una insulina de acción rápida? Circule las respuestas correctas.
a. Lantus
b. Novolog
c. Tresiba
d. Humalog
3. Al usar una bomba, ¿qué tipo de suministro de insulina debería mantener estable el
azúcar en la sangre cuando no está comiendo?
a. Basal
b. Bolus
c. Basal Temporal
4. Cuando se usa una bomba, ¿qué tipo de suministro de insulina se usa para cubrir los
alimentos ingeridos o para reducir el nivel alto de glucosa en la sangre?
a. Basal Temporal
b. Basal
c. Bolus
5. Si su hijo tiene un nivel alto de azúcar en la sangre y usted le da una dosis correctiva
de insulina con su bomba, ¿cuándo debe volver a verificar su nivel de azúcar en la
sangre para verificar que su bomba de insulina esté funcionando correctamente?
a. Cada 15 minutos durante 1 hora
b. 30 minutos después
c. 1 hora después
6. Si el nivel de azúcar en la sangre de su hijo no baja después de una dosis de
corrección administrada con la bomba, ¿qué debe hacer?
a. Llamar a su doctor
b. Chequear que su bomba esté funcionando como las indicaciones
c. Llamar al 911 o ir a la sala de emergencias
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7. ¿Cuál es la mayor cantidad de tiempo que su hijo puede desconectarse de la bomba
antes de que necesite controlar su nivel de azúcar en la sangre?
a. 30 minutos
b. 1 hora
c. 3 horas
c. 4-5 horas
8. Si su bomba falla, se le indica que siga la escala deslizante que se muestra aquí.
Si el nivel de
azucar esta en
este rango:
0-150
151-200
201-250
251-300
301-350
351-400

Unidades
de
Insulina
0
1
2
3
4
5

a. ¿Cuántas unidades tomarías para un azúcar en la sangre de 295? ___ unidades
b. ¿Qué tipo de insulina usarías si tu bomba deja de funcionar?
a. Humalog y Lantus
b. Solo Tresiba
c. Solo Humalog
d. Tresiba y Lantus
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Appendix E
Insulin Pump Vocabulary Review and Quiz in English and Spanish

Insulin Pump Vocabulary Review

TERM
Rapid- Acting Insulin

DEFINITION
Insulin that is used by the insulin pump.
Will begin to work about 15 minutes after
injection, peaks in about 1 hour, and
continues to work for 2 to 4 hours.

Basal rate

The continuous dose of insulin that is
delivered by the insulin pump 24 hours a
day, measured by insulin units per hour

Bolus

Extra insulin needed before meals and other
times when your child’s blood sugar is high

Temp basal rate

A basal rate that that you can set to the
amount of insulin temporarily delivered over
a given amount of time.

Insulin sensitivity factor (ISF) or
Correction Factor

The value that indicates how much one unit
of insulin will lower your child’s blood sugar

Active Insulin or Insulin on Board (IOB)

The length of time that insulin remains active
and available in your child’s body after a
bolus

Insulin to Carb Ratio

Amount of carbs (in grams) covered by one
unit of insulin

Target Blood glucose

The ideal range at which you would like your
blood sugar to be
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Insulin Pump Vocabulary Quiz
Match the term to the correct definition.
A. Basal Rate
B. Bolus
C. Temp Basal Rate
D. Insulin Sensitivity Factor/ Correction Factor
E. Insulin on Board
F. Insulin to Carb ratio
G. Target blood glucose

1. ______ The ideal range at which you would like your blood sugar to be.
2. ______ Amount of carbs (in grams) covered by one unit of insulin.
3. ______ The continuous dose of insulin that is delivered by the insulin pump
measured by insulin units per hour.
4. ______ The length of time that insulin remains active and available in your child’s
body after a bolus.
5. ______ A basal rate that that you can set to the amount of insulin temporarily
delivered over a given amount of time.
6. ______ The value that indicates how much one unit of insulin will lower your child’s
blood sugar.
7. ______ Extra insulin needed before meals and other times when your child’s blood
sugar is high.
8. ______ Insulin that is used by the insulin pump. Will begin to work about 15 minutes
after injection, peaks in about 1 hour, and continues to work for 2 to 4 hours.
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Revisión del vocabulario de la bomba de insulina

Término
Insulina de Accion Rápida

Basal rate
velocidad basal
Bolus
dosis de insulina rápida
Temp basal rate
velocidad basal temporaria

Definición
La insulina que usa la bomba de insulina.
Comenzará a funcionar aproximadamente
15 minutos después de la inyección,
alcanzará su punto máximo en
aproximadamente 1 hora y continuará
funcionando durante 2 a 4 horas.
La dosis continua de insulina suministrada
por la bomba de insulina que estará medida
por unidades de insulina por hora
La insulina adicional necesitada antes de las
comidas y otras veces cuando el nivel de
azúcar en la sangre de su hijo esta alto
Una dosis basal que usted puede programar
para suministrar temporalmente sobre un
tiempo elegido.

Insulin sensitivity factor (ISF) o
El valor que indica cuánto una unidad de
Correction Factor
insulina puede reducir el nivel de azúcar de
Factor de sensibilidad de la insulina o Factor la sangre de su hijo
de corrección
Active Insulin or Insulin on Board (IOB)
Insulina activa o insulina abordo

El tiempo que la insulina permanece activa y
disponible en el cuerpo de su hijo después
de un bolus

Insulin to Carb Ratio
Proporción de insulina a carbohidratos

Cantidad de carbohidratos (en gramos)
cubiertos por una unidad de insulina

Target Blood glucose
Objetivo del nivel de glucosa en la sangre

El rango ideal en el que le gustaría tener su
nivel de azúcar en sangre
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Cuestionario de vocabulario de la bomba de insulina
Elija el termino con la definición correcta.
H. Insulina de Accion Rapida
I. Basal Rate
J. Bolus
K. Temp Basal Rate
L. Insulin Sensitivity Factor
M. Insulin on Board
N. Insulin to Carb ratio
O. Target blood glucose
1. ______ El rango ideal en el que le gustaría tener su nivel de azúcar en sangre.
2. ______ Cantidad de carbohidratos (en gramos) cubiertos por una unidad de
insulina.
3. ______ La dosis continua de insulina suministrada por la bomba de insulina que
estará medida por unidades de insulina por hora.
4. ______ El tiempo que la insulina permanece activa y disponible en el cuerpo de
su hijo después de un bolus.
5. ______ Una dosis basal que usted puede programar para suministrar
temporalmente sobre un tiempo elegido.
6. ______ El valor que indica cuánto una unidad de insulina puede reducir el nivel
de azúcar de la sangre de su hijo.
7. ______ La insulina adicional antes de las comidas y otras veces cuando el nivel
de azúcar en sangre de su hijo esta alto.
8. ______ La insulina que usa la bomba de insulina. Comenzará a funcionar
aproximadamente 15 minutos después de la inyección, alcanzará su punto
máximo en aproximadamente 1 hora y continuará funcionando durante 2 a 4
horas.
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